Amelia D’Alessio

2.6k total citations · 2 hit papers
34 papers, 2.0k citations indexed

About

Amelia D’Alessio is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Amelia D’Alessio has authored 34 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Amelia D’Alessio's work include HER2/EGFR in Cancer Research (11 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Cancer-related Molecular Pathways (6 papers). Amelia D’Alessio is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Cancer-related Molecular Pathways (6 papers). Amelia D’Alessio collaborates with scholars based in Italy, United States and France. Amelia D’Alessio's co-authors include Nicola Normanno, Antonella De Luca, Monica R. Maiello, Marianna Gallo, Daniela Califano, Gennaro Chiappetta, Alfredo Fusco, Massimo Santoro, Alfonso Bellacosa and Maria Letizia Motti and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Academy of Management Journal.

In The Last Decade

Amelia D’Alessio

34 papers receiving 2.0k citations

Hit Papers

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pa... 2002 2026 2010 2018 2012 2002 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
    2012 581 citations Antonella De Luca, Monica R. Maiello et al. Expert Opinion on Therapeutic Targets profile →
  2. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer
    2002 562 citations Giuseppe Viglietto, Maria Letizia Motti et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amelia D’Alessio Italy 18 1.3k 822 412 247 182 34 2.0k
Randall Schreck United States 9 1.5k 1.2× 686 0.8× 469 1.1× 318 1.3× 176 1.0× 13 2.3k
Carolyn Cao United States 18 1.3k 1.0× 709 0.9× 402 1.0× 290 1.2× 114 0.6× 30 1.9k
Andreas Gschwind Germany 9 1.6k 1.3× 1.1k 1.3× 311 0.8× 294 1.2× 102 0.6× 10 2.7k
Nila U. Parikh United States 26 1.5k 1.1× 1.2k 1.5× 522 1.3× 314 1.3× 272 1.5× 39 2.5k
Anette Sommer Germany 25 1.2k 0.9× 699 0.9× 323 0.8× 189 0.8× 93 0.5× 63 2.0k
Juan Carlos Montero Spain 31 1.7k 1.3× 1.1k 1.4× 376 0.9× 233 0.9× 150 0.8× 90 2.8k
Jon Curwen United Kingdom 20 1.5k 1.1× 1.0k 1.2× 406 1.0× 634 2.6× 187 1.0× 31 2.7k
Yesim Gökmen‐Polar United States 26 1.1k 0.8× 430 0.5× 416 1.0× 163 0.7× 129 0.7× 92 1.7k
Minna M. Tanner Finland 10 1.5k 1.1× 626 0.8× 418 1.0× 209 0.8× 204 1.1× 17 2.3k
Richard Kendall United States 24 1.8k 1.4× 837 1.0× 476 1.2× 268 1.1× 238 1.3× 43 3.0k

Countries citing papers authored by Amelia D’Alessio

Since Specialization
Citations

This map shows the geographic impact of Amelia D’Alessio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amelia D’Alessio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amelia D’Alessio more than expected).

Fields of papers citing papers by Amelia D’Alessio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amelia D’Alessio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amelia D’Alessio. The network helps show where Amelia D’Alessio may publish in the future.

Co-authorship network of co-authors of Amelia D’Alessio

This figure shows the co-authorship network connecting the top 25 collaborators of Amelia D’Alessio. A scholar is included among the top collaborators of Amelia D’Alessio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amelia D’Alessio. Amelia D’Alessio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maiello, Monica R., Amelia D’Alessio, Simona Bevilacqua, et al.. (2015). EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. Journal of Cellular Biochemistry. 116(12). 2778–2785. 41 indexed citations
2.
Luca, Antonella De, Amelia D’Alessio, Monica R. Maiello, et al.. (2015). Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer. Expert Opinion on Drug Metabolism & Toxicology. 11(7). 1177–1185. 9 indexed citations
3.
Luca, Antonella De, Amelia D’Alessio, Monica R. Maiello, et al.. (2014). Vandetanib as a potential treatment for breast cancer. Expert Opinion on Investigational Drugs. 23(9). 1295–1303. 12 indexed citations
4.
Daniele, Gennaro, Marianna Gallo, Maria Carmela Piccirillo, et al.. (2013). Pharmacokinetic evaluation of capecitabine in breast cancer. Expert Opinion on Drug Metabolism & Toxicology. 9(2). 225–235. 9 indexed citations
5.
Luca, Antonella De, Amelia D’Alessio, Marianna Gallo, et al.. (2013). Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. Cell Cycle. 13(1). 148–156. 36 indexed citations
6.
Luca, Antonella De, et al.. (2012). The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opinion on Therapeutic Targets. 16(sup2). S17–S27. 581 indexed citations breakdown →
7.
Li, Jixia, Feng Zhu, Ronald A. Lubet, et al.. (2011). Quercetin‐3‐methyl ether inhibits lapatinib‐sensitive and ‐resistant breast cancer cell growth by inducing G2/M arrest and apoptosis. Molecular Carcinogenesis. 52(2). 134–143. 37 indexed citations
8.
Luca, Antonella De, Luana Lamura, Marianna Gallo, et al.. (2011). Pharmacokinetic evaluation of zoledronic acid. Expert Opinion on Drug Metabolism & Toxicology. 7(7). 911–918. 15 indexed citations
9.
Luca, Antonella De, Marianna Gallo, Donatella Aldinucci, et al.. (2010). Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. Journal of Cellular Physiology. 226(8). 2131–2138. 81 indexed citations
10.
Normanno, Nicola, et al.. (2009). Prognostic Applications of Gene Expression Signatures in Breast Cancer. Oncology. 77(Suppl. 1). 2–8. 14 indexed citations
11.
Luca, Antonella De, Marianna Gallo, Monica R. Maiello, et al.. (2008). Zoledronic acid affects the expression of VEGF in breast cancer cells and in bone marrow stromal cells through direct and indirect mechanisms. Cancer Research. 68. 294–294. 1 indexed citations
12.
D’Alessio, Amelia, Laura Cerchia, Ivano Amelio, et al.. (2007). Shp2 in PC12 cells: NGF versus EGF signalling. Cellular Signalling. 19(6). 1193–1200. 11 indexed citations
13.
Normanno, Nicola, Manuela Campiglio, Monica R. Maiello, et al.. (2007). Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Research and Treatment. 112(1). 25–33. 42 indexed citations
14.
Incoronato, Mariarosaria, Amelia D’Alessio, Simona Paladino, et al.. (2004). The Shp-1 and Shp-2, tyrosine phosphatases, are recruited on cell membrane in two distinct molecular complexes including Ret oncogenes. Cellular Signalling. 16(7). 847–856. 10 indexed citations
15.
Viglietto, Giuseppe, Maria Letizia Motti, Paola Bruni, et al.. (2002). Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nature Medicine. 8(10). 1136–1144. 562 indexed citations breakdown →
16.
D’Alessio, Amelia, Daniela Califano, Gaetano Calı̀, et al.. (2000). Abrogation of Nerve Growth Factor-induced Terminal Differentiation by ret Oncogene Involves Perturbation of Nuclear Translocation of ERK. Journal of Biological Chemistry. 275(25). 19306–19314. 35 indexed citations
17.
Califano, Daniela, Claudia Rizzo, Amelia D’Alessio, et al.. (2000). Signaling through Ras Is Essential for retOncogene-induced Cell Differentiation in PC12 Cells. Journal of Biological Chemistry. 275(25). 19297–19305. 49 indexed citations
18.
Rizzo, Claudia, Daniela Califano, Gabriella De Vita, et al.. (1996). Ligand Stimulation of a Ret Chimeric Receptor Carrying the Activating Mutation Responsible for the Multiple Endocrine Neoplasia Type 2B. Journal of Biological Chemistry. 271(46). 29497–29501. 14 indexed citations
19.
Santelli, Giovanni, et al.. (1995). DBL Expression Driven by the Neuron Specific Enolase Promoter Induces Tumor Formation in Transgenic Mice with a P53(±) Genetic Background. Biochemical and Biophysical Research Communications. 216(3). 762–770. 11 indexed citations
20.
Santelli, Giovanni, Vittorio de Franciscis, Gennaro Chiappetta, et al.. (1993). Thyroid Specific Expression of the Ki-ras Oncogene in Transgenic Mice. Advances in experimental medicine and biology. 348. 59–62. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Randall Schreck Breakdown of academic impact, for papers by Carolyn Cao Breakdown of academic impact, for papers by Andreas Gschwind Breakdown of academic impact, for papers by Nila U. Parikh Breakdown of academic impact, for papers by Anette Sommer Breakdown of academic impact, for papers by Juan Carlos Montero Breakdown of academic impact, for papers by Jon Curwen Breakdown of academic impact, for papers by Yesim Gökmen‐Polar Breakdown of academic impact, for papers by Minna M. Tanner Breakdown of academic impact, for papers by Richard Kendall
Rankless by CCL
2026